Further studies have employed computational approaches to identify the immunotherapy targets such as CAMKV in neuroblastoma patients presenting with MYCN or GPC2 amplification in high-risk neuroblastoma [152,153]. This evidence concerns the gene MYCN and neuroblastoma.